CTFA/CHPA Urge Expanded Oral Health Care Indications
This article was originally published in The Rose Sheet
Executive Summary
FDA should broaden labeling guidance for the indications of OTC antigingivitis/antiplaque drug products to allow multiple descriptions of drug effects, the Joint Oral Care Task Group of the Consumer Healthcare Products Association and the Cosmetic, Toiletry and Fragrance Association recommends
You may also be interested in...
Combination Oral Health Care Product Safety Defended By Industry
Combination oral health care products should be permitted in the antigingivitis/antiplaque final monograph, according to the Joint Oral Care Task Group of the Consumer Healthcare Products Association and the Cosmetic, Toiletry and Fragrance Association
Combination Oral Health Care Product Safety Defended By Industry
Combination oral health care products should be permitted in the antigingivitis/antiplaque final monograph, according to the Joint Oral Care Task Group of the Consumer Healthcare Products Association and the Cosmetic, Toiletry and Fragrance Association
Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR
FDA's advance notice of proposed rulemaking on OTC antigingivitis/antiplaque products excludes the combination of antigingivitis/antiplaque ingredients with other oral health care ingredients. The 1notice was published in the May 29 Federal Register